Stockscreener 앱 받기
2.27
5.58%
0.12
전일 마감가:
$2.15
열려 있는:
$2.18
하루 거래량:
1.49M
Relative Volume:
1.76
시가총액:
$67.20M
수익:
-
순이익/손실:
$-30.15M
주가수익비율:
-0.5675
EPS:
-4
순현금흐름:
$-21.66M
1주 성능:
+2.25%
1개월 성능:
+8.10%
6개월 성능:
-24.58%
1년 성능:
-46.71%
1일 변동 폭
$2.155
$2.38
1주일 범위
$2.00
$2.38
52주 변동 폭
$1.58
$4.2753
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
명칭
Nrx Pharmaceuticals Inc
전화
484-254-6134
주소
1201 ORANGE STREET, WILMINGTON
NRXP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
2.27 | 63.65M | 0 | -30.15M | -21.66M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-08 | 개시 | H.C. Wainwright | Buy |
| 2025-04-02 | 개시 | BTIG Research | Buy |
Nrx Pharmaceuticals Inc 주식(NRXP)의 최신 뉴스
NRXP Stock: Ascendiant Capital Raises Price Target to $48 | NRXP - GuruFocus
Milestone Patient Data Eclipsing 70,000 on Real World Use - openPR.com
NRx Pharmaceuticals Addresses Nasdaq Meeting Compliance Requirements - TipRanks
NRx Pharmaceuticals Received Notice of Noncompliance - TradingView — Track All Markets
NRx Pharmaceuticals Announces 2025 Annual Meeting Date and Record Date - Investing News Network
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date - The Manila Times
Shareholders face Jan. 26 deadline for NRx 2025 meeting proposals - Stock Titan
Sentiment Review: What are NRx Pharmaceuticals Incs recent SEC filings showingPortfolio Return Summary & AI Forecasted Entry/Exit Points - baoquankhu1.vn
NRx Pharmaceuticals Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be submitted to the FDA in Support of NRX-100 Approval - marketscreener.com
Biotech NRx Pharma outlines its business at H.C. Wainwright investor event - Stock Titan
NRx Pharmaceuticals (NASDAQ:NRXP) Given "Buy" Rating at BTIG Research - MarketBeat
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval - Sahm
FinancialContentMilestone Patient Data Eclipsing 70,000 on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - FinancialContent
NRx Pharmaceuticals (NASDAQ: NRXP) Licenses Real-World Evidence From 70,000 Patients to Support FDA Accelerated Approval of NRX-100 - Digital Journal
NRx Pharmaceuticals Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression - citybiz
NRXP stock slips premarket as NRx says FDA fast-tracked ketamine bid with 70,000-patient dataset - TechStock²
Why Did NRXP Stock Surge 21% Pre-Market Today? - Stocktwits
NRx Pharmaceuticals' NRX-100 Receives FDA Fast Track Designation for Treatment of Suicidal Ideation in Depression and Bipolar Depression - Quiver Quantitative
Is NRx Pharmaceuticals Inc backed by strong institutional buying2025 Sector Review & Verified Stock Trade Ideas - baoquankhu1.vn
Earnings Report: Should I hold or sell NRx Pharmaceuticals Inc Equity Warrant stock in 2025Quarterly Trade Review & Daily Oversold Bounce Ideas - Bộ Nội Vụ
Retail Surge: Whats the beta of NRx Pharmaceuticals Inc stockWeekly Trade Report & Stepwise Swing Trade Plans - baoquankhu1.vn
Published on: 2026-01-11 15:15:08 - ulpravda.ru
How institutional buying supports NRx Pharmaceuticals Inc. Equity Warrant stockJuly 2025 Sentiment & High Return Trade Guides - Улправда
Why NRx Pharmaceuticals Inc. Equity Warrant stock remains a top recommendationJuly 2025 Closing Moves & Fast Exit Strategy with Risk Control - ulpravda.ru
Will NRx Pharmaceuticals Inc. Equity Warrant stock rally after Fed decisionsAnalyst Upgrade & Verified Technical Signals - ulpravda.ru
Why NRx Pharmaceuticals Inc. Equity Warrant stock appeals to dividend seekersWeekly Investment Recap & Risk Managed Investment Strategies - Улправда
Can NRx Pharmaceuticals Inc. stock withstand economic slowdownWeekly Market Report & Technical Entry and Exit Alerts - ulpravda.ru
Will NRx Pharmaceuticals Inc. Equity Warrant stock outperform value stocksWeekly Earnings Recap & Consistent Profit Trading Strategies - ulpravda.ru
Market Recap: Is NRx Pharmaceuticals Inc. Equity Warrant stock in correction or buying zoneJuly 2025 Earnings & Safe Capital Allocation Plans - ulpravda.ru
PRN_FinancialWrapper | PR NewswireNRX Pharmaceuticals, Inc.Warrant (Nasdaq:NRXPW) Stock Quote - FinancialContent
Can NRx Pharmaceuticals Inc. stock beat market expectations this quarterWeekly Risk Report & Daily Chart Pattern Signal Reports - ulpravda.ru
NRX Pharmaceuticals, Inc.Common Stock (NQ: NRXP - FinancialContent
Why NRx Pharmaceuticals Inc. Equity Warrant stock attracts global investorsLow Beta Stocks & Start Your Free Trading Journey Today - ulpravda.ru
NRXP SEC FilingsNrx Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
A High-Stakes Alliance Aims to Standardize Mental Health Care at Scale - MyChesCo
NRx and neurocare partner to create nationwide neuroplastic care network By Investing.com - Investing.com Nigeria
Will NRx Pharmaceuticals Inc. Equity Warrant stock reach all time highs in 20252026 world cup usa national team semifinals star players set piece tactics odds analysis preview - ulpravda.ru
NRx Pharmaceuticals (NASDAQ: NRXP) Partners With neurocare Group AG To Build Nationwide Neuroplastic Care Network - Digital Journal
NRx Pharmaceuticals and neurocare group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and Other Mental Health Afflictions - citybiz
About Us - FinancialContent
D. Boral Capital Reaffirms "Buy" Rating for NRx Pharmaceuticals (NASDAQ:NRXP) - MarketBeat
NRx Pharmaceuticals and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions - Investing News Network
NRx and neurocare partner to create nationwide neuroplastic care network - Investing.com
NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions - The Manila Times
NRx Pharmaceuticals and neurocare Group AG Launch Integrated Nationwide Network for Neuroplastic Therapy to Combat Depression and PTSD - Quiver Quantitative
NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG - GlobeNewswire
Ulta Beauty To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Breakout Zone: Is NRx Pharmaceuticals Inc Equity Warrant stock in correction or buying zone2025 Growth vs Value & Safe Entry Trade Signal Reports - moha.gov.vn
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
NRx Pharmaceuticals Completes Debt Repayment, Ends 2025 Debt-Free - The Globe and Mail
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Short Interest Up 38.2% in December - MarketBeat
Nrx Pharmaceuticals Inc (NRXP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):